Results 61 to 70 of about 2,212 (184)
Evaluation of the Effect of IL‐1 Antagonists on Pituitary Function
Background Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease frequently observed in populations along the Eastern Mediterranean coast, characterized by recurrent fever, abdominal pain, and joint inflammation. The disease results from mutations in the MEFV gene, which plays a critical role in regulating IL‐1β secretion ...
Fadime Aktas Koc +3 more
wiley +1 more source
Recurrent pericarditis (RP) occurs in 15% to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids.
Perrin R. +14 more
core +1 more source
BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1
Dennis D. Arnold (13003734) +2 more
core +1 more source
Gout is a crystal deposition disease caused by raised levels of uric acid in the blood (hyperuricaemia) with persistence of hyperuricemia at levels higher than a serum saturation of 6.8 mg/dl leads to formation of monosodium urate (MSU) crystals and ...
Hanan Abdel Rehim
doaj +1 more source
Targeted Anti‐Inflammatory Therapy in Cardiovascular Events: Challenges and Opportunities
ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally. Emerging evidence suggests that inflammation plays a pivotal role in the pathogenesis of atherosclerosis and subsequent cardiovascular events. Traditional treatments primarily focus on lipid‐lowering and antithrombotic strategies; however, these ...
Li Feng +3 more
wiley +1 more source
BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1
Dennis D. Arnold (13003734) +2 more
core +1 more source
Canakinumab i rilonacept per al tractament de les síndromes periòdiques associades a la criopirina [PDF]
Síndromes periòdiques associades a criopirina; Canakinumab; Assaigs clínics; Rilonacept;Cryopyrin-Associates Periodic Syndrome; CAP; Clinical Trial; Síndromes periódicos asociados a criopirina; Ensayos ClínicosLes síndromes periòdiques associades a ...
Comitè d’Avaluació de Medicaments d’Ús Hospitalari (CAMUH)
core +1 more source
Interleukin-1: from discovery to therapeutic targeting of the first cytokine
Interleukin-1 (IL-1) was the first cytokine to be discovered and remains one of the most instructive molecules in immunology, linking fundamental mechanisms of innate immune activation to human inflammatory disease and targeted therapy.
Lori Broderick +2 more
doaj +1 more source
Biologics and Small‐Molecule Therapies in Netherton Syndrome: A Comprehensive Review
ABSTRACT Netherton syndrome (NS) is a rare congenital ichthyosis caused by loss‐of‐function mutations in the SPINK5 gene, leading to defective expression of the serine protease inhibitor LEKTI. Dysregulated epidermal protease activity results in impaired skin barrier function and chronic inflammation, accompanied by complex immune profiles. NS patients
Shin Morizane +6 more
wiley +1 more source
The changing face of AS. This diagram illustrates the research landscape of ASCAD. It highlights a shift in understanding from viewing it as a lipid storage disease to recognizing it as a chronic inflammatory disease. Additionally, emerging therapies like colchicine, methotrexate, IL‐1 blockade, IL‐6 blockade, darapladib, and low‐dose IL‐2 are being ...
Kan Wang +4 more
wiley +1 more source

